Difference between revisions of "Otlertuzumab (TRU-016)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "7 PubMed" to "7/ PubMed") |
||
(19 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
==Preliminary data== | ==Preliminary data== | ||
− | # Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. [https:// | + | ===[[Chronic lymphocytic leukemia]]=== |
− | # | + | # '''Phase I:''' Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. [https://pubmed.ncbi.nlm.nih.gov/24381226/ PubMed] |
− | + | # '''TRU-016:''' Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15. [https://doi.org/10.1111/bjh.14464 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324531/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27977057/ PubMed] | |
− | [ | + | ===Other=== |
− | + | # '''Phase I:''' Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014 Dec;32(6):1213-25. Epub 2014 Jun 15. [https://pubmed.ncbi.nlm.nih.gov/24927856/ PubMed] | |
− | [ | + | # Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015 Jan;168(1):38-45. Epub 2014 Aug 22. [https://pubmed.ncbi.nlm.nih.gov/25146490/ PubMed] |
− | + | ==Also known as== | |
− | + | *'''Code name:''' TRU-016 | |
− | [[Category:Investigational]] | + | [[Category:Drugs]] |
+ | |||
+ | [[Category:Intravenous medications]] | ||
+ | |||
+ | |||
+ | [[Category:Anti-CD37 antibodies]] | ||
+ | |||
+ | [[Category:Investigational drugs]] |
Latest revision as of 14:04, 4 May 2023
Mechanism of action
Anti-CD37 antibody. CD37 is a cell surface tetraspanin.
Preliminary data
Chronic lymphocytic leukemia
- Phase I: Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. PubMed
- TRU-016: Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15. link to original article link to PMC article PubMed
Other
- Phase I: Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014 Dec;32(6):1213-25. Epub 2014 Jun 15. PubMed
- Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015 Jan;168(1):38-45. Epub 2014 Aug 22. PubMed
Also known as
- Code name: TRU-016